Can curative antivirals benefit porphyria cutanea tarda in hepatitis C patients?

Hatch, Michael M.; Nawas, Zeena Y.; Kollipara, Ramya; Sk, Tyring

doi:10.1111/jdv.13936

Cited by 12 publications

(7 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Tong, Song, and Tyring () described 3 men with HCV who had resolution of their PCT manifestations months after completing an 8‐ or 12‐ week combination regimen of ledipasvir, 90 mg and sofosbuvir, 400 mg. This report confirms the previous observation by Hatch et al () and paves the way for a new, cheap therapy with excellent safety profile for PCT.…”

supporting

confidence: 91%

“…Regular phlebotomy schedule and low‐dose hydroxychloroquine are effective and safe treatment options (Arora et al, ). Hatch, Nawas, Kollipara, and Tyring () first reported a man with PCT who experienced resolution of the lesions when he started treatment with ledipasvir 90/sofosbuvir 400 mg. Recently, Tong, Song, and Tyring () described 3 men with HCV who had resolution of their PCT manifestations months after completing an 8‐ or 12‐ week combination regimen of ledipasvir, 90 mg and sofosbuvir, 400 mg.…”

mentioning

confidence: 99%

“…Regular phlebotomy schedule and low-dose hydroxychloroquine are effective and safe treatment options (Arora et al, 2016). Hatch, Nawas, Kollipara, and Tyring (2016) first reported a man with PCT who experienced resolution of the lesions when he started treatment with ledipasvir 90/sofosbuvir 400 mg. Recently, Tong, Song, and Tyring (2016)…”

mentioning

confidence: 99%

See 2 more Smart Citations

Anti-HCV for porphyria cutanea tarda

Abdelmaksoud

2017

Dermatologic Therapy

View full text Add to dashboard Cite

supporting

confidence: 91%

mentioning

confidence: 99%

See 1 more Smart Citation

Anti-HCV for porphyria cutanea tarda

Abdelmaksoud

2017

Dermatologic Therapy

View full text Add to dashboard Cite

“…There is limited literature on the efficacy of DAAs in patients with PCT. Two cases of patients treated with ledipasvir and sofosbuvir experienced resolution of PCT lesions with treatment . A larger case series of 13 HCV‐PCT patients (only some of whom received DAA‐only therapy) also reported efficacy, with nine patients on DAA‐only therapy achieving SVR .…”

Section: Porphyria Cutanea Tardamentioning

confidence: 94%

“…Two cases of patients treated with ledipasvir and sofosbuvir experienced resolution of PCT lesions with treatment. 82,83 A larger case series of 13 HCV-PCT patients (only some of whom received DAA-only therapy) also reported efficacy, with nine patients on DAA-only therapy achieving SVR. 84 Of the two patients with active PCT on DAAs, both had clinical improvement in their lesions and plasma porphyrins.…”

Section: Porphyria Cutanea Tardamentioning

confidence: 95%

Hepatitis C virus and its cutaneous manifestations: treatment in the direct‐acting antiviral era

Wiznia

Laird

Franks

2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

New all-oral direct-acting antivirals (DAA) have changed the hepatitis C virus (HCV) treatment landscape. Given that dermatologists frequently encounter HCV-infected patients, knowledge of the current treatment options and their utility in treating HCV-associated dermatologic disorders is important. In addition to highlighting the new treatment options, we review four classically HCV-associated dermatologic disorders - mixed cryoglobulinaemia (MC), lichen planus (LP), porphyria cutanea tarda (PCT) and necrolytic acral erythema (NAE) - and examine the role for all-oral direct-acting antiviral (DAA) regimens in their treatment. A literature search of English-language publications was conducted of the PubMed and EMBASE databases using search terms including 'hepatitis C', 'direct acting antivirals', 'cutaneous', 'mixed cryoglobulinemia', 'necrolytic acral erythema', 'lichen planus', 'porphyria cutanea tarda', 'rash', as well as specific drug names, related terms and abbreviations. Currently, limited data exist on the use of DAAs in HCV-infected patients with cutaneous side-effects, although treatment of the underlying HCV is now recommended for nearly all patients, with the new drugs offering much-improved dosage schedules and side-effect profiles. The most data exist for MC, in which several studies suggest that DAAs and achievement of sustained virologic response (SVR) improve cutaneous symptoms. Studies of both older and newer regimens are limited by their small size, retrospective nature, lack of appropriate controls and wide variability in study protocols. Given the strong association, screening for HCV should be considered in patients with MC, LP, PCT and NAE.

show abstract

Hepatic Manifestations of Systemic Disorders

Gordon

González

2017

Schiff's Diseases of the Liver

View full text Add to dashboard Cite

Can curative antivirals benefit porphyria cutanea tarda in hepatitis C patients?

Cited by 12 publications

References 4 publications

Anti-HCV for porphyria cutanea tarda

Anti-HCV for porphyria cutanea tarda

Hepatitis C virus and its cutaneous manifestations: treatment in the direct‐acting antiviral era

Hepatic Manifestations of Systemic Disorders

Contact Info

Product

Resources

About